WALTHAM, Mass.--(BUSINESS WIRE)--May 14, 2018--
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of tumor
drug resistance, today announced that members of the management team
will present at the following upcoming investor conferences:
- UBS Global Healthcare Conference on Monday, May 21, 2018 at 8:30 AM
ET. The conference is being held at the Grand Hyatt New York in New
York City.
- Jefferies Global Healthcare Conference on Thursday, June 7, 2018 at
1:30 PM ET. The conference is being held at the Grand Hyatt New York
in New York City.
A live webcast of the events will be available on the “Events and
Presentations” page in the “Investors” section of the Company’s website
at https://investors.deciphera.com/news-events/events-presentations.
A replay of the webcasts will be archived on the Company’s website for
90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on improving the lives of cancer patients by tackling key
mechanisms of drug resistance that limit the rate and/or durability of
response to existing cancer therapies. Our small molecule drug
candidates are directed against an important family of enzymes called
kinases, known to be directly involved in the growth and spread of many
cancers. We use our deep understanding of kinase biology together with a
proprietary chemistry library to purposefully design compounds that
maintain kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed to
address therapeutic resistance causing mutations and immuno-targeted
agents designed to control the activation of immunokinases that suppress
critical immune system regulators, such as macrophages. We have used our
platform to develop a diverse pipeline of tumor-targeted and
immuno-targeted drug candidates designed to improve outcomes for
patients with cancer by improving the quality, rate and/or durability of
their responses to treatment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180514005233/en/
Source: Deciphera Pharmaceuticals, Inc.
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investor
Relations:
Argot Partners
Laura Perry, 212-600-1902
Laura@argotpartners.com
or
Sam
Martin, 212-600-1902
Sam@argotpartners.com
or
Company:
Deciphera
Pharmaceuticals, LLC
Christopher J. Morl, 781-209-6418
Chief
Business Officer
cmorl@deciphera.com
